EICHOR
● Recruiting
Redirected HBV-Specific T Cells in Patients With HBV-related HCC (SAFE-T-HBV)
Condition: Hepatocellular Carcinoma · Sponsor: Lion TCR Pte. Ltd.
About this study
This is a single center, single arm and open-label study to determine the safety of mRNA modified HBV-TCR redirected T-cells and to analyze the changes in tumor microenvironment caused by these HBV-TCR redirected T-cells in subjects with HBV-related HCC who are not amenable to/failed conventional treatment.
This description comes directly from the study's public registry record.
Talk to the study team
Royce Fam · 69260818 · royce.fam@liontcr.com
Always discuss trial participation with your own doctor first.
Locations (1)
| Singapore General Hospital | Singapore, Singapore | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04745403